Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder
- PMID: 28284329
- DOI: 10.1016/j.jneuroim.2017.01.024
Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder
Abstract
Soluble CD40 ligand (sCD40L) is reported to disrupt the blood-brain barrier (BBB). Cerebrospinal fluid (CSF) and serum sCD40L levels were measured in 29 multiple sclerosis (MS), 29 neuromyelitis optica spectrum disorder (NMOSD), and 27 disease control (DC) patients. In MS, serum sCD40L levels were higher than in DCs and positively correlated with the CSF/serum albumin ratio (Qalb). In NMOSD, CSF sCD40L levels were significantly increased compared to DCs, and were correlated to Qalb, CSF cell counts, protein concentrations, and interleukin-6 levels. sCD40L could be involved in BBB disruption in MS, whereas it may contribute to CNS inflammation in NMOSD.
Keywords: Blood-brain barrier; CD40 ligand; Central nervous system; Cerebrospinal fluid; Multiple sclerosis; Neuromyelitis optica.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Different roles of soluble CD40 ligand in central nervous system damage.Neurol Res. 2020 May;42(5):372-378. doi: 10.1080/01616412.2020.1716469. Epub 2020 Mar 16. Neurol Res. 2020. PMID: 32178599
-
Impact of blood-brain barrier disruption on newly diagnosed neuromyelitis optica spectrum disorder symptoms and prognosis.Ann Palliat Med. 2020 Mar;9(2):324-330. doi: 10.21037/apm.2019.12.12. Ann Palliat Med. 2020. PMID: 32268769
-
Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.Mult Scler. 2017 Jul;23(8):1072-1084. doi: 10.1177/1352458516672015. Epub 2016 Sep 28. Mult Scler. 2017. PMID: 27682231
-
Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.Mediators Inflamm. 2016;2016:5314541. doi: 10.1155/2016/5314541. Epub 2016 Jan 28. Mediators Inflamm. 2016. PMID: 26941483 Free PMC article. Review.
-
Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.Int J Mol Sci. 2016 Nov 15;17(11):1894. doi: 10.3390/ijms17111894. Int J Mol Sci. 2016. PMID: 27854301 Free PMC article. Review.
Cited by
-
CD40-CD40L in Neurological Disease.Int J Mol Sci. 2022 Apr 8;23(8):4115. doi: 10.3390/ijms23084115. Int J Mol Sci. 2022. PMID: 35456932 Free PMC article. Review.
-
The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.Front Immunol. 2017 Dec 12;8:1791. doi: 10.3389/fimmu.2017.01791. eCollection 2017. Front Immunol. 2017. PMID: 29312317 Free PMC article. Review.
-
Effects of intermittent hypoxia with thrombin in an in vitro model of human brain endothelial cells and their impact on PAR-1/PAR-3 cleavage.Sci Rep. 2022 Jul 19;12(1):12305. doi: 10.1038/s41598-022-15592-x. Sci Rep. 2022. PMID: 35853902 Free PMC article.
-
Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder.Clin Exp Immunol. 2020 Nov;202(2):239-248. doi: 10.1111/cei.13487. Epub 2020 Jul 23. Clin Exp Immunol. 2020. PMID: 32643149 Free PMC article.
-
Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis.J Cent Nerv Syst Dis. 2021 Oct 25;13:11795735211050712. doi: 10.1177/11795735211050712. eCollection 2021. J Cent Nerv Syst Dis. 2021. PMID: 34720605 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials